BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Feb. 10, 2020

Feb. 10, 2020
Biopharmas raising money in public or private financings, including: Adaptimmune, Assertio, Collegium, Mereo.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Med-tech firms raising money in public or private financings, including: Aurora Spine.
Read More
2-7-Sensome-Clotild.png

Sensome raises $9M series B funding round for Clotild guidewire

Feb. 7, 2020
By Bernard Banga
PARIS – Sensome SAS, of Palaiseau, France, has closed a second funding round, of $9 million, with its original French investors (Kurma Partners SA, Invest Partners SA, BNP Paribas Développement SA and the Paris-Saclay Seed Fund), now joined by the Japanese-based Asahi Intecc Co. Ltd.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Biopharmas raising money in public or private financings, including: Adma, AGTC, Dare, Inventiva, Miragen, Orphazyme, Phio, Rapt, Salarius, Tonix.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Med-tech firms raising money in public or private financings, including: Connectyx Technologies, Lunaphore Technologies, Pentixapharm, Rewalk Robotics.
Read More
European Union flag, coins

Azafaros closes $28M series A for dual-acting enzyme inhibitors in lysosomal storage disease

Feb. 6, 2020
By Cormac Sheridan
DUBLIN – Azafaros BV raised €25 million (US$27.5 million) to develop orally available azasugar drugs with potential application to multiple lysosomal storage diseases.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Biopharmas raising money in public or private financings, including: AGTC, Arch Biopartners, Atyr, Beam, Chi-Med, Cortexyme, Kineticos, Moleculin, Pentixapharm, Sonoma, Valo.
Read More
2-5-Lumos-Febridx.png

Lumos Diagnostics scoops up $15M in series A to back Febridx test

Feb. 5, 2020
By Liz Hollis
With an eye toward expanding the reach of its Febridx rapid point-of-care (POC) test, Lumos Diagnostics Holdings Pty. Ltd. has seen the closing of a $15 million series A round from Australia’s Planet Innovation. The funds will back a U.S. FDA pivotal clinical trial, as well as additional development and manufacturing resources for the company’s expanding full-service POC business.
Read More

Maat Pharma edges toward FMT data readout with $20M series B round

Feb. 5, 2020
By Cormac Sheridan
DUBLIN – Maat Pharma SA closed an €18 million (US$19.9 million) series B round to continue development of its standardized, off-the-shelf fecal microbiota transplant (FMT) therapy, MaaT-013.
Read More

Financings for Feb. 5, 2020

Feb. 5, 2020
Med-tech firms raising money in public or private financings, including: Integra Lifesciences Holdings, Itamar Medical, Jenavalve Technology, Verana Health.
Read More
Previous 1 2 … 627 628 629 630 631 632 633 634 635 … 675 676 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing